Curevac announces financial results for the third quarter and first nine months of 2021 and provides business update

Strategic focusing on second-generation mrna program jointly developed with gsk after withdrawal of first-generation covid-19 vaccine candidate, cvncov, from regulatory review nature publication of promising pre-clinical results for second-generation covid-19 vaccine candidate, cv2cov, in study with harvard medical school, showing comparable immune response to a licensed mrna vaccine positive developments across rest of the pipeline, including pre-clinical results in molecular therapies and progress of phase 1 study with lead candidate in oncology re-allocation of existing manufacturing lines and capacities to support second-generation program and streamlining of external manufacturing network cash position of €1.06 billion as of september 30, 2021. curevac continues to assess supplier commitments related to the withdrawal of first-generation covid-19 vaccine candidate curevac will host a webcast and conference call on friday, november 19, 2021, at 8 a.m.
CVAC Ratings Summary
CVAC Quant Ranking